米国における禁煙補助薬の市場

U.S. Smoking Cessation Drug Market

発行	Frost & Sullivan
出版日	2007年12月	商品コード	58567
ページ情報	英文 85 Pages
価格	US$ 6,000 換算 ¥ 482,820 (税抜) Web Access (Regional License) US$ 6,500 換算 ¥ 523,055 (税抜) Hard Copy & Web Access (Regional License)

概要
原文目次
関連レポート

原文目次

Abstract

This research service covers the U.S. smoking cessation drug market from 2003-2013. Included are a therapeutic overview, patient forecasts, total market revenue forecasts, product revenue forecasts, and market share analysis. The market is segmented by product: Zyban, Chantix, and emerging products. Major market challenges, drivers, restraints, and strategic recommendations to overcome market challenges are also discussed.

1 EXECUTIVE SUMMARY

Executive Summary
- Introduction

2 MARKET INTRODUCTION

Research Scope and Methodology
- Scope and Segmentation
- Research Methodology
Smoking Overview
- Introduction
- Smoking Statistics
- Components of Cigarettes
- Reasons To Quit Smoking
- Health Risks of Smoking
- Health Benefits from Quitting Smoking
- Treatment Options
Market Overview
- Market Engineering Measurements
- Industry Challenges
- Market Drivers
- Market Restraints

3 MARKET ANALYSIS

Competitive Analysis
- Competitive Structure
Product Analysis
- Zyban
- Chantix
Emerging Products
- Emerging Smoking Cessation Drugs
- Emerging Smoking Cessation Vaccines
Patient Forecasts
- Patient Forecasts
Revenue Forecasts
- Total Market Revenue Forecasts
- Revenue Forecasts By Product
Market Share Analysis
- Company Market Share

4 APPENDIX

Decision Support Databases
- Incidence of Lung Cancer
- Prevalence of Coronary Heart Disease
- Total Cases of Stroke
- Prevalence of COPD
- Prevalence of Smokers